# First-in-Human Exploratory Single Ascending Dose of GLPG0974

> **NCT01496937** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GLPG0974
- **DRUG:** GLPG0974

## Key facts

- **NCT ID:** NCT01496937
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2012-01
- **Final completion:** 2012-02
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2012-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01496937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01496937, "First-in-Human Exploratory Single Ascending Dose of GLPG0974". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01496937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*